



Unconventional Antiviral Agents

Guest Editors:

Prof. Dr. Sara N. Richter

Department of Molecular
Medicine, University of Padua,
Padua, Italy

Prof. Dr. Louis Flamand

Department of Microbiology,
Infectious Diseases and
Immunology, Faculty of Medicine
Laval University and Division of
Infectious and Immune Diseases,
CHU de Quebec Research Center-
Université Laval, Quebec City,
Canada

Deadline for manuscript
submissions:

closed (1 December 2020)

Message from the Guest Editors

Dear Colleagues,

The activity of current antiviral agents is limited to a few viruses, such as HIV, herpes viruses, HBV/HCV, and the influenza viruses. The available drugs target a limited number of viral steps, i.e., replication and transcription by inhibition of polymerases and integrases; protein maturation by targeting proteases; and entry, uncoating, and budding by modification or hindrance of virus attachment and surface proteins or cell receptors. While these activities effectively prevent/suppress viral replication, most of the time they do not eradicate the virus from the host, especially when chronic infections or latency are involved. Moreover, drug-resistant viruses, new virus variants, and new virus species that do not respond to any of the current antiviral treatments constantly emerge and are becoming an increasingly urgent priority.

In this Special Issue, we aim to explore new ways to combat viral infections. In particular, we welcome research on new compounds with antiviral activity, with unconventional targets and mechanisms of action against all types of viruses.

Prof. Dr. Sara N. Richter

Prof. Dr. Louis Flamand

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and
Replication Program, Center for
Cancer Research, National
Cancer Institute, Frederick, MD
21702-1201, USA

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.**

Journal Rank: JCR - Q2 (*Virology*) / CiteScore - Q1 (Infectious Diseases)

Contact Us

Viruses Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/viruses
viruses@mdpi.com
[X@VirusesMDPI](https://twitter.com/VirusesMDPI)